objectives To assess long-term antiretroviral therapy (ART) outcomes during rapid HIV programme expansion in the public sector of Eswatini (formerly Swaziland).
Introduction
Because 4.1 million more people living with HIV (PLHIV) require HIV treatment for achievement of the second 90 of the UNAIDS 90-90-90 cascade targets in Eastern and Southern Africa [1, 2] , effective and universal antiretroviral therapy (ART) provision remains the backbone of successful HIV programmes [2] . WHO recommends a public health-oriented approach for antiretroviral provision in resource-limited settings (RLS), allowing for simplification of HIV services, service decentralisation and integration into tuberculosis (TB) and primary care settings, task-shifting and expansion of treatment eligibility criteria [3] [4] [5] [6] [7] . Despite the unprecedented progress in ART provision (e.g. 60% ART coverage in sub-Saharan Africa in 2017) [1, 8] , achievements remain fragile as challenges persist in funding, medical capacity, slow uptake and implementation of international recommendations, health service infrastructure, healthcare staffing, laboratory monitoring services, drug supply and programme monitoring [9] [10] [11] [12] [13] [14] . Suboptimal ART retention has raised particular concern because large and rapidly expanding ART programmes appear to encounter greater challenges in retaining patients [15, 16] . ART retention was 78% at 12 months in low-and middle-income countries [15] , and several studies found increased rates of loss to follow-up (LTFU) in recent years [16] [17] [18] [19] [20] [21] [22] , while mortality remained stable [17, 20] or decreased [17, 18, 21, 22] . The mismatch of growing demand for ART and overburdened health facilities likely contributed to deterioration in quality of care, suboptimal adherence and treatment support and poorer record keeping [16, 17, 21] . The feasibility of continued ART expansion -through the introduction of the WHO treatall approach endorsing prompt ART initiation irrespective of immunological status -remains uncertain and has resulted in doubts about its likely impact [10] [11] [12] [23] [24] [25] [26] [27] [28] .
Eswatini (formerly Swaziland) has the highest HIV prevalence (32% in adults aged 18-49 years) [29] and one of the highest TB notification and HIV co-infection rates in the world [30] . Despite limited resources for the HIV response [31, 32] , estimated HIV incidence decreased by 44% (from 2.5 to 1.4 cases per 100 personyears) between 2011 and 2016 [33] . Population-level viral load suppression among PLHIV was 73% in Eswatini and highest (79%) in the southern Shiselweni region [33, 34] , surpassing the international UNAIDS population-level target of 73% (1). Although the Eswatini ART response was considered a success story before the most recent guidance to drop all treatment eligibility criteria (treat-all), contemporary large ART cohort analyses with extended patient follow-up are lacking. We describe temporal trends in the growth and programmatic outcomes of the HIV treatment programme in the Shiselweni region of Eswatini, establishing a baseline against which to evaluate further treatment expansion, and drawing lessons to inform the implementation of universal treatment access.
Methods

Setting
The predominantly rural Shiselweni region (population 210 000 (35)) in southern Eswatini has an HIV prevalence of 26% in people aged ≥ 15 years [34] . Several programmatic strategies were applied during ART expansion between 2006 and 2014 (Table 1) . From 2006 to 2007, HIV-TB care was centralised at outpatient departments of three secondary health facilities (two health centres, one hospital) in three health clusters (Nhlangano, Hlathikulu, Matsanjeni) (period-1). In 2008, doctor-led mobile outreach teams started decentralising HIV-TB services, with physical integration into 22 nurse-led primary care clinics from 2009 to 2010 (period-2). Nurses were trained to perform ART and TB treatment initiation and follow-up. Trained lay cadres provided HIV counselling and testing, basic laboratory tests (e.g. point-of-care CD4 cell count testing, biochemistry testing), medication ART, antiretroviral therapy; PLHIV, people living with HIV; PMTCT, prevention of mother-to-child transmission. *Patients established on ART were also transferred down from secondary to primary care facilities. †Continued strengthening and streamlining of vertical integration of HIV and TB services as well as horizontal integration into routine primary care services. ‡One of the three health zones (Nhlangano health zone) provided the WHO treat-all programmatic approach with ART initiation irrespective of CD4 and WHO staging criteria from October 2014.
§PMTCT option B+ was provided in Nhlangano health zone from January 2013. Thereafter, it was phased in in the other two health zones from August 2014. ¶Mobile teams provided HIV-TB care in a few facilities.
dispensing, pre-treatment counselling and treatment adherence support interventions. The WHO 2010 treatment guidelines were also endorsed in 2010. Thereafter, from 2011 to 2012, HIV services were consolidated, and community-based HIV testing and routine viral load monitoring were introduced [36, 37] (period-3). Then, in 2013 and 2014 (period-4), ART eligibility was further extended in Nhlangano health cluster by phasing in the prevention of mother-to-child transmission (PMTCT) option B+ approach in 01/2013 [38, 39] and universal ART provision irrespective of immunological criteria (treat-all) in 10/2014. All services were provided free of charge by the Ministry of Health and M edecins Sans Fronti eres (MSF). A map of facilities of Shiselweni is presented in Figure S1 :1.
Study design and definitions
We analysed a retrospectively established cohort of HIVinfected adults (≥16 years) initiated on standard first-line ART in 25 health facilities in the Shiselweni region between 01/2006 and 12/2014. Data came from the national ART treatment database used for routine programmatic monitoring by the Ministry of Health. Exclusion criteria were transfer in from outside the region, missing age or being on a non-standard first-line treatment regimen. Follow-up was from the day of ART initiation until the earliest of the composite outcome of allcause attrition (death or LTFU), transfer out of the region and database closure (08/2015). LTFU was defined as ≥ 6 months without a clinic visit, measured on the date of last clinic visit.
Statistics
First, we described patients' baseline characteristics by calendar year and overall. Median and interquartile ranges (IQR) were used for continuous variables, and frequencies and proportions for categorical variables. Differences across categories were tested with Pearson's chisquared test. Second, to estimate programmatic impact, we calculated the number of patients alive and retained in care at each calendar mid-year, and obtained annual ART coverage estimates. The denominator was PLHIV, obtained by multiplying regional projected annual mid-year population estimates [35] by regional HIV prevalence estimates for ≥15-year-olds [34] . ART retention was calculated for each annual cohort separately using the Kaplan-Meier estimator.
Third, calendar years were grouped into corresponding programmatic periods (1-4) (Figure 1 ) for inclusion into covariate-adjusted regression analysis, where time to attrition was the outcome. Other covariates for inclusion were determined a priori. We used multiple imputation by chained equations for imputation of missing covariate values of sex-pregnancy status, CD4 cell count, WHO staging, body mass index (BMI), creatinine, alanine aminotransferase (ALT), haemoglobin and access to telephone, creating 20 imputed datasets [40] . Then we used flexible parametric survival models (Royston-Parmar models) [41, 42] to describe the association between time to attrition and the covariates, and plotted averaged survival curves based on the fitted model [43] . The number of internal knots for estimating the baseline spline function was based on Akaike's and Schwarz's Bayesian information criteria and on visual inspection of best fit of standardised survival and hazard curves. After assessment of the proportional hazards assumption with Schoenfeld residual statistics, we allowed the variable programmatic period to vary by duration on ART. Two regression models were built: the first included all available variables irrespective of magnitude of missingness (Model-1), and the second was restricted to covariates with < 20% imputed values (Model-2). In the sensitivity analysis, calendar year (instead of programmatic period) was allowed to interact with follow-up time. All analyses were performed with Stata 14.1 (StataCorp, College Station, Texas, US). 
Ethics
Results
Baseline characteristic and temporal trends
Baseline characteristics and temporal trends are presented in Tables 2-3 . A reciprocal proportional decrease was seen for the age group 35-54 years, from 46% to 29%. The sex of 0.2% of patients was unknown and pregnancy status was missing in 16% of women. Most patients were non-pregnant women (n = 11 987, 54%), followed by men (n = 8493, 38%) and pregnant women (n = 1643, 7%). Most patients (n = 15 613, 94%) had access to a telephone.
Most patients had CD4 cell counts of ≤100 (28%), 101-200 (28%) and 201-350 (33%) cells/mm 3 , while 12% had counts ≥351 cells/mm 3 . The median CD4 cell count increased in each consecutive year, most pronounced in pregnant women (from 78 to 343.5 cells/mm The most widely used nucleoside reverse transcriptase inhibitor drugs were zidovudine (AZT) (39%) and tenofovir disoproxil fumarate (TDF) (48%). In 2006, 80% and 18% of patients received stavudine (D4T) and AZT compared with 89% and 10% receiving TDF and AZT in 2014 (Figure 1 ). D4T was largely phased out between 2009 and 2010, while TDF was phased in. Abacavir (ABC) was rarely used in all calendar years (≤1%). In 2006, the main non-nucleoside reverse transcriptase inhibitor drug was nevirapine (NVP) (68%), while efavirenz (EFV) use increased rapidly from 2011, reaching 91% in 2014. Men 539 (36) 580 (35) 827 (35) 1012 (34) 1228 (35) 1187 (35) 1112 (37) 1020 (32) 988 (31) 8493 (34) Non-pregnant women 248 (17) 462 (28) 880 (37) 1625 (55) 1959 (55) 1781 (53) 1557 (51) 1729 (54) 1746 (55) 11 987 (48) Pregnant women 3 (0) 30 (2) 86 (4) 119 (4) 172 (5) 245 (7) 268 (9) 337 (11) 383 (12) 1643 (7) Missing* 698 (47) 583 (35) 561 (24) 195 (7) 177 (5) 156 (5) 102 (3) 102 (3) 75 (2) 2649 (11) Age, years (missing n 34 (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) 35 (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) 34 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) 33 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) 33 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) 32 (26-41) 31 (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) 33 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) 16-24
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439 (30) 459 (28) 645 (27) 762 (26) 879 (25) 805 (24) 712 (23) 689 (22) 654 (20) 6044 (24) 45-54
234 (16) 212 (13) 346 (15) 449 (15) 476 (13) 437 (13) 382 (13) 364 (11) 291 (9) 3191 (13) ≥55 106 (7) 138 (8) 185 (8) 291 (10) 298 (8) 246 (7) 233 (8) 213 (7) 201 (6) 1911 ( 677 (41) 824 (35) 917 (31) 911 (26) 820 (24) 759 (25) 642 (20) 616 (19) 6817 (28) 101-200
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16 (1) 23 (1) 17 (1) 33 (1) 116 (3) 106 (3) 78 (3) 268 (8) 412 (13) 1069 (4) WHO staging (missing n = 13) I+II 615 (41) 718 (43) 1027 (44) 1462 (50) 1927 (55) 2030 (60) 1989 (65) 2448 (77) 2561 (80) 14 777 (60) III 676 (45) 754 (46) 1077 (46) 1230 (42) 1407 (40) 1159 (34) 907 (30) 637 (20) 542 (17) 8389 (34) IV 196 (13) 183 (11) 249 (11) 258 (9) 200 (6) 177 (5) 141 (5) 101 (3) 88 (3) 1593 (6) NRTI (missing n = 0)
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16 (1) 23 (1) 60 (2) 1043 (29) 2670 (79) 2422 (80) 2802 (88) 2825 (89) 11 879 (48) NNRTI (missing n = 0) EFV 475 (32) 465 (28) 506 (21) 824 (28) 1411 (40) 2771 (82) 2456 (81) 2832 (89) 2892 (91) 14 632 (59) NVP 1013 (68) 1190 (72) 1848 (79) 2127 (72) 2125 (60) 598 (18) 583 (19) 356 (11) 300 (9) 10 140 (41) n, number; IQR, interquartile range; WHO, World Health Organization; NRTI, nucleoside reverse transcriptase inhibitor; AZT, zidovudine; ABC, abacavir; D4T, stavudine; TDF, tenofovir disoproxil fumarate; NNRTI, non-nucleoside reverse transcriptase inhibitors; EFV, efavirenz; NVP, nevirapine. *The greatest proportion of missing values was for pregnancy status (11%), while only <1% had missing sex status. Laboratory measures for creatinine, ALT and haemoglobin were frequently not available at baseline (60%). Among patients with complete observations (Table 3) 
Programmatic impact
The number of people active on ART increased in consecutive years from 2171 in 2006 to 18 307 in 2014 (8.4-fold increase). While the relative increase was similar for both sexes (women 8.5-vs. men 8.3-fold increase), more women (n = 12 210, 67%) were on ART in 2014. In 2014, 9782 (53%) patients were followed at primary care level and 5477 (30%) at secondary care level, and 3048 (17%) did not have the healthcare level recorded. The ART coverage among PLHIV increased 8.0-fold, from 7.1% in 2006 to 56.8% in 2014 (Figure 2) .
Crude ART retention increased in consecutive annual ART cohorts (Figure 3) . The 12-month retention was 71% in 2006 compared with 86% in 2014. After 9 years of follow-up of the 2006 ART cohort, 49% patients were retained in care. Improvements in retention were most pronounced comparing programmatic periods (Figure 3) : retention was 66%, 74%, 80% and 82% at 2 years for consecutive periods 1-4.
Associations with attrition
The total and median follow-up times were 77 009.8 and 2.6 (IQR 1.0-4.9) years, with 1666 (7%) deaths and 5681 (23%) LTFU recorded at a rate of 9.5 (95% confidence interval [CI] 9.3-9.8) per 100 person-years. Imputation diagnostic and model selection procedures are presented in Appendices S2-S3.
While only findings of Model-1 are described here (Table 3) , estimates were comparable between the models (Appendix S4, Table S4 Compared with non-pregnant women, men had a 23% (aHR 1.23, 1.15-1.32) increased risk of attrition while pregnant women had a 10% increased risk (aHR 1.10, 0.98-1.23) (Appendix S4, Figure S4:2a) . Compared with the reference age group 25-34 years, attrition was increased for young adults (16-24 years) and patients aged ≥ 55 years, while it was decreased for patients aged 35-54 years. The availability of a phone While Model-2 (Appendix S4, Table S4 :1) showed increased risk of attrition for ABC (aHR 1.34, 95% CI 1.04-1.73) and D4T (aHR 1.57, 1.47-1.69) compared with AZT, Model-1 showed an increased risk only for D4T (aHR 1.16, 1.05-1.28).
Discussion
This study describes temporal trends and outcomes of public sector ART programme expansion in a predominantly rural setting over 9 years. Crude attrition decreased over time coinciding with an 8-fold expansion of the treatment cohort and an increase in ART coverage. The same trend was seen in covariate-adjusted analysis of attrition, coinciding with programmatic changes over time.
Results in context
Crude ART retention of the 2010 annual cohort and thereafter compares favourably with retention reported from routine low-and middle-income settings (78% at 12 months, 71% at 24 months and 69% at 36 months) [15] . In contrast to other studies suggesting higher attrition for more recent cohorts [15, 21] , attrition decreased with each consecutive programmatic period and was reduced by 20% in 2012-2014. Firstly, one study from neighbouring South Africa ceased patient follow-up during the early years of programme expansion [21] , possibly missing positive trends once HIV-TB programmes had been consolidated. Secondly, the implementation of combination interventions -ART provision at higher CD4 thresholds, prescription of less toxic drug combinations -may have supported ART expansion while maintaining and improving outcomes. Active defaulter tracing by phone (with possibility of physical tracing by home visits) may also have contributed, as patients with access to a phone had a 35% decreased risk of attrition. Other studies showed that programmes applying physical defaulter tracing had higher 12-month retention on ART (80.0% vs. 75.8%) [44] and programmes using phones in combination interventions had reduced loss to care [44] [45] [46] [47] . Sensitivity analysis, however, suggested a temporary increase in risk of attrition in 2008, the year when HIV-TB care was decentralised through mobile doctor-led teams. The rapid introduction of new programmatic and clinical activities (decentralisation, task-shifting and sharing, provision of ART and TB treatment in previous ART-TB 'na€ ıve' primary care clinics) facilitated access to ART but may have overwhelmed the health system and health workers. Although attrition showed a tendency of decline since 2010 (the end of the decentralisation period), the full gains became evident later Similar to other studies, young age [17, 32, [48] [49] [50] [51] [52] [53] , sex-pregnancy status [17, 32, 48, 49, 51, [54] [55] [56] , pathological baseline laboratory test results [48] , more toxic drug regimens (e.g. D4T) [53] , advanced WHO III/ IV staging [32, 48, [50] [51] [52] [53] 56] and low CD4 cell counts [17, [48] [49] [50] 52] increased the risk of an adverse outcome. Notably, patients with CD4 cell counts above 350 cells/ mm 3 had similar outcomes to patients with CD4 cell count 201-350 cells/mm 3 , suggesting that expansion of ART eligibility through the WHO treat-all approach is feasible for healthier individuals.
Explanation of results and programmatic lessons learnt
Service decentralisation and integration, task-shifting, simplification of HIV care, viral load testing and innovative care models were found efficient to support ART expansion in RLS [7, 51-54, 57, 58, 59] . In this setting, timely identification of programmatic obstacles and overcoming them with effective combination interventions were likely contributing factors for improved programmatic outcomes.
First, the highly centralised set-up of HIV-TB care provision required decentralisation and integration of services into rural primary care clinics to increase access and facilitate the programmatic and clinical management of HIV-TB co-infection. Second, the human resources for health crisis intertwined with lack of patient support structures necessitated task-shifting and sharing. Nurses were capacitated to diagnose and treat HIV-TB with only limited doctor support. Lay people living with HIV from the surrounding communities were trained to provide basic clinic services and patient support. Third, to increase access to timely treatment, international policy changes were quickly implemented (e.g. 2010 WHO treatment eligibility recommendations) and pilot interventions for treatment expansion were introduced before becoming WHO policy (e.g. phase-in of PMTCT option B+ [38, 39] and treat-all). This allowed an increasing number of PLHIV to start treatment before presenting with advanced HIV disease, possibly resulting in a less sick and clinically more easy to manage treatment cohort. In this study, however, only a limited number of patients were exposed to the most recent policy changes (PMTCT option B+, treat-all), thus making it difficult to analyse the possible impact of these changes on patient outcomes. Fourth, the establishment of phlebotomist-led minilaboratories at primary care clinics allowed for point-ofcare CD4, haemoglobin and biochemistry (creatinine, ALT) testing [60] . This was likely to support rapid ART initiation and timely clinical decision-making by reducing turnaround time between sample collection and result delivery. Fifth, the introduction of routine viral load monitoring and enhanced adherence counselling for patients with elevated viral loads [37, 61] was likely to reduce mortality, LTFU and development of drug resistance [62, 63] . Although the findings of this study can be considered favourable, other programmatic constraints such as suboptimal linkage to care from routine community-based (34%) and facility-based (87%) HIV testing [36, 45] undetectable viral load (<100 copies/mL) [61] and 89% of pregnant and lactating women achieving viral suppression (<1000 copies/mL) [39] . Future programmatic changes such as simplification of ART provision under the treat-all approach and the introduction of potent antiretroviral drugs (e.g. dolutegravir) could have the potential to further improve outcomes. The 2017 WHO recommendation on rapid and same-day ART initiation is also expected to improve rates of treatment initiation, time to viral suppression and treatment outcomes [64, 65] .
Strengths and weaknesses
Although the introduction of specific programmatic and health policy factors coincided with improved outcomes over time, this study was not designed to assess causal relationships. The efficacy and real-world effectiveness of the intervention in routine settings were discussed previously [66] [67] [68] . Bias could have been introduced by not adjusting for other undocumented factors possibly associated with the outcome (e.g. TB co-infection, socioeconomic and facility-level factors). Treatment interruptions were not taken into account as longitudinal visit data were not available. This may have overestimated LTFU for more recent cohorts with shorter follow-up time [69] . Exclusion of treatment interrupters re-entering ART care may underestimate programmatic impact if the reason for return was a defaulter tracing intervention integrated into the ART programme. Because ascertainment of patient outcomes was weak and we had no access to national death registries, LTFU and death were combined into the composite outcome of all-cause attrition. Thus, we were likely to miss separate temporal trends in mortality and LTFU as reported from other settings [16] [17] [18] [19] [20] [21] [22] . It was beyond the scope of this study to assess HIV testing, linkage to HIV care and viral load suppression, all factors crucial to estimating the overall success of large HIV programmes. Finally, despite the overall success of this HIV treatment programme, outcomes of children remained unknown as the analysis was limited to young people and adults. A strength of the study was the use of international recommendations for definitions of LTFU and methodological approaches to ART survival analysis [70, 71] . In addition, flexible parametric survival methods allowed us to easily model programmatic period as a time-dependent factor and to understand its impact on survival over time. As this study originated from the public sector ART programme, findings are likely generalisable to other similar rural and resource-poor settings in sub-Saharan Africa.
Conclusions
Documenting and measuring previous progress in ART programming provides lessons for future treatment expansion. In this setting, public sector ART expansion was feasible and yielded improved programmatic outcomes over time. HIV-TB service decentralisation and integration, task-shifting and progressive changes in treatment eligibility were likely key factors facilitating access to ART and increasing treatment coverage. After years of ART programming, this setting appears prepared for continued treatment expansion through the WHO treat-all approach.
